Simplified Chinese
Phasing Out the Three-Dose Regimen: A New Strategy for Adult Hepatitis B Vaccination
Release date:
2019-05-27
Author:
Article/Excerpted from Vaccine Circle
Source:
Abstract
How much do you know about HBV?
Humans are the only natural host of HBV, and the population is generally susceptible. Epidemiological studies indicate that China currently has approximately 93 million chronic HBV carriers. More than 50% of new cases each year occur in individuals aged 20 to 40, underscoring the critical importance of hepatitis B prevention among adults—particularly those with compromised immune function, including men, older adults, obese individuals, smokers, heavy drinkers, and people with chronic comorbidities.
Protecting and supporting liver health hinges on prevention.
Recommendation 4 from the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B” (2015 edition): For individuals with compromised immune function or those who fail to respond, the vaccine dose should be increased (e.g., to 60 μg) and the number of doses expanded. For those who do not respond to a three-dose vaccination schedule, an additional dose of 60 μg or a three‑dose regimen of 20 μg recombinant yeast‑derived hepatitis B vaccine may be administered; serum anti‑HBs levels should be assessed 1–2 months after the second dose. If no response persists, a further dose of 60 μg recombinant yeast‑derived hepatitis B vaccine may be given (A1).
Classification of Hepatitis B Vaccines for Adults
Adult hepatitis B vaccines available on the market are categorized into two types: the 20 µg recombinant hepatitis B vaccine and the 60 µg recombinant hepatitis B vaccine.
Among them, the 20 µg recombinant hepatitis B vaccine follows the standard three-dose schedule, with a vaccination course lasting up to six months. In contrast, the 60 µg recombinant hepatitis B vaccine requires only two doses for primary immunization, completing the course in just two months; moreover, a single dose is sufficient for individuals who exhibit a poor immune response, thereby minimizing missed doses and enabling rapid antibody development for effective protection.
The 60 µg recombinant hepatitis B vaccine demonstrates good efficacy in healthy individuals aged 16 years and older who are receiving their first vaccination series.
For individuals who have failed to achieve protective immunity following the standard hepatitis B vaccination series, administration of a 60 µg recombinant hepatitis B vaccine can also elicit a robust immune response.
Studies have shown that a 0–2‑month vaccination schedule using a 60 µg recombinant hepatitis B vaccine can rapidly elicit protective antibodies in both the primary immunization cohort aged 16 years and older and in individuals with low or non‑responders.
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account